154 related articles for article (PubMed ID: 23749103)
1. Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Société Française des Cancers de l'Enfant and the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Paillard C; Rochette E; Lutz P; Bertrand Y; Michel G; Bordigoni P; Dalle JH; Rohrlich P; Vannier JP; Perel Y; Plantaz D; Leverger G; Sirvent A; Dore E; Isfan F; Merlin E; Pereira B; Halle P; Rabiau N; Kanold J; Deméocq F
Bone Marrow Transplant; 2013 Nov; 48(11):1401-8. PubMed ID: 23749103
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
3. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.
Malard F; Milpied N; Blaise D; Chevallier P; Michallet M; Lioure B; Clément L; Hicheri Y; Cordonnier C; Huynh A; Yakoub-Agha I; Peffault de Latour R; Mohty M
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1059-67. PubMed ID: 25708220
[TBL] [Abstract][Full Text] [Related]
4. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
Le Gouill S; Milpied N; Buzyn A; De Latour RP; Vernant JP; Mohty M; Moles MP; Bouabdallah K; Bulabois CE; Dupuis J; Rio B; Gratecos N; Yakoub-Agha I; Attal M; Tournilhac O; Decaudin D; Bourhis JH; Blaise D; Volteau C; Michallet M;
J Clin Oncol; 2008 May; 26(14):2264-71. PubMed ID: 18390969
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
Park S; Labopin M; Yakoub-Agha I; Delaunay J; Dhedin N; Deconinck E; Michallet M; Robin M; De Revel T; Bernard M; Vey N; Lioure B; Lapusan S; Tabrizi R; Bourhis JH; Huynh A; Beguin Y; Socié G; Dreyfus F; Fenaux P; Mohty M
Eur J Haematol; 2013 May; 90(5):355-64. PubMed ID: 23320648
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Robin M; Tabrizi R; Mohty M; Furst S; Michallet M; Bay JO; Cahn JY; De Coninck E; Dhedin N; Bernard M; Rio B; Buzyn A; Huynh A; Bilger K; Bordigoni P; Contentin N; Porcher R; Socié G; Milpied N
Br J Haematol; 2011 Feb; 152(3):331-9. PubMed ID: 21133885
[TBL] [Abstract][Full Text] [Related]
8. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Damaj G; Mohty M; Robin M; Michallet M; Chevallier P; Beguin Y; Nguyen S; Bories P; Blaise D; Maillard N; Rubio MT; Fegueux N; Cornillon J; Clavert A; Huynh A; Adès L; Thiébaut-Bertrand A; Hermine O; Vigouroux S; Fenaux P; Duhamel A; Yakoub-Agha I
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1349-55. PubMed ID: 24838178
[TBL] [Abstract][Full Text] [Related]
9. Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
de Berranger E; Cousien A; Petit A; Peffault de Latour R; Galambrun C; Bertrand Y; Salmon A; Rialland F; Rohrlich PS; Vannier JP; Lutz P; Yakouben K; Duhamel A; Bruno B; Michel G; Dalle JH
Bone Marrow Transplant; 2014 Mar; 49(3):382-8. PubMed ID: 24317131
[TBL] [Abstract][Full Text] [Related]
10. Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Chantepie SP; Mohty M; Tabrizi R; Robin M; Deconinck E; Buzyn A; Contentin N; Raus N; Lhéritier V; Reman O
Bone Marrow Transplant; 2013 May; 48(5):684-90. PubMed ID: 23165497
[TBL] [Abstract][Full Text] [Related]
11. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
[TBL] [Abstract][Full Text] [Related]
12. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
13. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis.
Ruggeri A; Rocha V; Masson E; Labopin M; Cunha R; Absi L; Boudifa A; Coeffic B; Devys A; De Matteis M; Dubois V; Hanau D; Hau F; Jollet I; Masson D; Pedron B; Perrier P; Picard C; Ramouneau-Pigot A; Volt F; Charron D; Gluckman E; Loiseau P
Haematologica; 2013 Jul; 98(7):1154-60. PubMed ID: 23242594
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.
Styczynski J; Tallamy B; Waxman I; van de Ven C; Milone MC; Shaw LM; Harrison L; Morris E; Satwani P; Bhatia M; George D; Bradley MB; Garvin JH; Schwartz J; Baxter-Lowe LA; Cairo MS
Bone Marrow Transplant; 2011 Jun; 46(6):790-9. PubMed ID: 20818441
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire.
Xavier E; Cornillon J; Ruggeri A; Chevallier P; Cornelissen JJ; Andersen NS; Maillard N; Nguyen S; Blaise D; Deconinck E; Veelken H; Milpied N; Van Gelder M; Peffault de Latour R; Gluckman E; Kröger N; Schetelig J; Rocha V
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1515-23. PubMed ID: 25958294
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Millot F; Esperou H; Bordigoni P; Dalle JH; Michallet M; Michel G; Bourhis JL; Kuenz M; Blaise D; Garban F; Plouvier E; Rome A; Guilhot J; Guilhot F
Bone Marrow Transplant; 2003 Nov; 32(10):993-9. PubMed ID: 14595387
[TBL] [Abstract][Full Text] [Related]
17. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire.
Mohty M; Labopin M; Balère ML; Socié G; Milpied N; Tabrizi R; Ifrah N; Hicheri Y; Dhedin N; Michallet M; Buzyn A; Cahn JY; Bourhis JH; Blaise D; Raffoux C; Espérou H; Yakoub-Agha I
Leukemia; 2010 Nov; 24(11):1867-74. PubMed ID: 20882046
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience.
Strullu M; Rialland F; Cahu X; Brissot E; Corradini N; Thomas C; Blin N; Rialland X; Méchinaud F; Mohty M
Eur J Haematol; 2012 Jun; 88(6):504-9. PubMed ID: 22372430
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
